A New Orally Active, Aminothiol Radioprotector-Free of Nausea and Hypotension Side Effects at Its Highest Radioprotective Doses
Authors:
- Timothy A. HackerTHTimothy A. Hacker
- William E. FahlWFWilliam E. Fahl
- 1 April 2012
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 82 (5) , e701-e707
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Combined treatment with cytoprotective agents and radiotherapyCancer Treatment Reviews, 2010
- Olvanil: A non-pungent TRPV1 activator has anti-emetic properties in the ferretNeuropharmacology, 2009
- History and development of radiation-protective agentsInternational Journal of Radiation Biology, 2009
- American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy ProtectantsJournal of Clinical Oncology, 2009
- Pharmacological Agents for the Prevention and Treatment of Toxic Radiation Exposure in SpaceflightAviation, Space, and Environmental Medicine, 2008
- Radiation Dose to Patients From Cardiac Diagnostic ImagingCirculation, 2007
- Animal Models for Radiation Injury, Protection and TherapyRadiation Research, 2005
- Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.Journal of Clinical Oncology, 1996
- Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trialCancer, 1992
- Final report on phase i trial of WR-2721 before protracted fractionated radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1988